DNA

$6.83

Post-MarketAs of Mar 17, 8:00 PM UTC

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$6.83
Potential Upside
5%
Whystock Fair Value$7.17
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and develop...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$422.94M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.59
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-51.08%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
4.66

Recent News

Simply Wall St.
Mar 14, 2026

How The Ginkgo Bioworks (DNA) Story Is Shifting As Analysts Revisit Growth And Risk

Analysts have been trimming their price targets on Ginkgo Bioworks Holdings, with bullish views moving to about US$12 from US$14 and more cautious calls dropping to around US$5 from US$9. These shifts line up with a more mixed narrative, where some analysts still see long term potential, while others are more focused on execution risk and the impact of recent business changes. As you read on, you will see how to track these evolving views and what they might mean for your own research on the...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 1, 2026

A Look At Ginkgo Bioworks (DNA) Valuation After Earnings Update And Invaio Collaboration

Why Ginkgo Bioworks is back on investors’ radar Ginkgo Bioworks Holdings (DNA) has drawn fresh attention after reporting full year 2025 results that paired lower sales with a smaller net loss, alongside a new collaboration with Invaio Sciences on peptide based crop protection. See our latest analysis for Ginkgo Bioworks Holdings. The earnings release and Invaio collaboration have landed against a tough backdrop, with Ginkgo Bioworks Holdings’ 1 day share price return of 30.48% decline at...

BEARISH
Negative press. News cycle fixated on risk factors or misses.
MarketBeat
Feb 28, 2026

Ginkgo Bioworks Q4 Earnings Call Highlights

Ginkgo Bioworks (NYSE:DNA) used its fourth-quarter earnings call to outline a sharpened strategic focus for 2026 centered on “autonomous labs,” while also detailing year-over-year declines in cell engineering revenue and continued progress on expense reductions and cash burn. 2026 focus shifts towa

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Feb 28, 2026

Ginkgo Bioworks Holdings Inc (DNA) Q4 2025 Earnings Call Highlights: Strategic Shifts and ...

Ginkgo Bioworks Holdings Inc (DNA) focuses on autonomous labs and cash burn reduction while navigating revenue declines and restructuring impacts.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Moby
Feb 27, 2026

Ginkgo Bioworks Holdings, Inc. Q4 2025 Earnings Call Summary

Moby summary of Ginkgo Bioworks Holdings, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.